FDA says Pfizer’s new RSV vaccine may trigger debilitating Guillain-Barre syndrome in some older adults

At this rate, Big Pharma is going to risk turning the entire population against vaccines of any nature.

Amid all the blowback over potentially harmful side effects of the Covid-19 vaccine, despite continued reassurance that it’s safe, the Food and Drug Administration issued a warning that Pfizer’s new RSV vaccine for older adults may trigger painful and potentially deadly Guillain-Barre syndrome, according to the Daily Mail.

“In clinical trials, two participants in their 60s developed the condition that can also cause crippling pain, muscle weakness and paralysis,” the British newspaper reported. “One of the patients recovered after three months, but the second took six months to return to normal. They were among 20,000 adults who got the experimental shot.”

There were no cases on GBS in the control group that did not get the vaccine, prompting the FDA to ask Pfizer to conduct a safety review before approving the vaccine.

There is currently no shot to prevent RSV, which stands for respiratory syncytial virus,  a winter respiratory bug that kills up to 10,000 adults over 65 in the U.S. every year, according to the Daily Mail. There is currently no shot against the disease available.

Guillain-Barre sees the immune system go haywire and start to attack nerve cells, triggering symptoms including muscle pain, numbness and pins and needles.

The Mayo Clinic describes Guillain-Barre as “a rare disorder in which your body’s immune system attacks your nerves. Weakness and tingling in your hands and feet are usually the first symptoms. These sensations can quickly spread, eventually paralyzing your whole body.”

The article noted that the condition was also recorded during trials of a rival RSV vaccine made by UK-based pharmaceutical giant GSK, and that it has been previously reported in people who got AstraZeneca’s Covid vaccine, which was not approved for use in the U.S.

Here’s more from the Daily Mail:

One of the patients to develop the syndrome in Pfizer’s trial was an American man in his 60s with a history of high blood pressure.

He suffered lower back pain eight days after vaccination and experienced weakness in his legs on the 14th day. After suffering a fall, the man was hospitalized and subsequently diagnosed with the syndrome. His symptoms resolved in six months. The patient also suffered a heart attack, but the FDA said this was not related to the RSV vaccine.

In the second case, a woman in her 60s in Japan with a history of type 2 diabetes developed a variant of the syndrome, called Miller-Fisher syndrome. Miller-Fisher tends to affect the upper body first, whereas Guillain-Barre typically affects the lower body and then spreads upwards.

She experienced fatigue nine days after vaccination and, on day ten, suffered from a sore throat and poor muscle control. She was hospitalized 19 days after vaccination. Her symptoms cleared within three months.


Forbes reported last week that Pfizer announced the FDA had granted a priority review for its vaccine candidate designed to protect newborns and infants up to six months of age against severe disease and complications from RSV, this being achieved by “immunizing pregnant people.”

“The decision means the agency aims to review the application within six months instead of the standard 10,” Forbes noted, adding that the FDA has set an “action date” on the vaccine for August.

Republished with permission from American Wire News Service


Please help us! If you are fed up with letting radical big tech execs, phony fact-checkers, tyrannical liberals and a lying mainstream media have unprecedented power over your news please consider making a donation to BPR to help us fight them. Now is the time. Truth has never been more critical!

Success! Thank you for donating. Please share BPR content to help combat the lies.
Tom Tillison


We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.

PLEASE JOIN OUR NEW COMMENT SYSTEM! We love hearing from our readers and invite you to join us for feedback and great conversation. If you've commented with us before, we'll need you to re-input your email address for this. The public will not see it and we do not share it.

Latest Articles